Literature DB >> 26628630

Myeloproliferative neoplasms and personalized medicine: the perfect match?

Jean-Jacques Kiladjian1, Claire Harrison2.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26628630      PMCID： PMC4666324          DOI： 10.3324/haematol.2015.137182

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  25 in total

1.  Clonal analysis of erythroid progenitors suggests that pegylated interferon alpha-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells.

Authors:  J-J Kiladjian; A Massé; B Cassinat; H Mokrani; I Teyssandier; J-P le Couédic; N Cambier; C Almire; E Pronier; N Casadevall; W Vainchenker; C Chomienne; F Delhommeau
Journal:  Leukemia       Date:  2010-06-03       Impact factor: 11.528

2.  Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Authors:  Peter J Campbell; Linda M Scott; Georgina Buck; Keith Wheatley; Clare L East; Joanne T Marsden; Audrey Duffy; Elaine M Boyd; Anthony J Bench; Mike A Scott; George S Vassiliou; Donald W Milligan; Steve R Smith; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Claire N Harrison; Anthony R Green
Journal:  Lancet       Date:  2005-12-03       Impact factor: 79.321

3.  Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.

Authors:  Jean-Jacques Kiladjian; Bruno Cassinat; Sylvie Chevret; Pascal Turlure; Nathalie Cambier; Murielle Roussel; Sylvia Bellucci; Bernard Grandchamp; Christine Chomienne; Pierre Fenaux
Journal:  Blood       Date:  2008-07-23       Impact factor: 22.113

4.  Some speculations on the myeloproliferative syndromes.

Authors:  W DAMESHEK
Journal:  Blood       Date:  1951-04       Impact factor: 22.113

5.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

6.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

7.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544

Review 8.  Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera.

Authors:  Claire Harrison
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2010

Review 9.  The spectrum of JAK2-positive myeloproliferative neoplasms.

Authors:  Jean-Jacques Kiladjian
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2012

10.  Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.

Authors:  Rami S Komrokji; John F Seymour; Andrew W Roberts; Martha Wadleigh; L Bik To; Robyn Scherber; Elyce Turba; Andrew Dorr; Joy Zhu; Lixia Wang; Tanya Granston; Mary S Campbell; Ruben A Mesa
Journal:  Blood       Date:  2015-03-11       Impact factor: 22.113
View more
  2 in total

Review 1.  Progress in elucidation of molecular pathophysiology of myeloproliferative neoplasms and its application to therapeutic decisions.

Authors:  Ruochen Jia; Robert Kralovics
Journal:  Int J Hematol       Date:  2019-11-18       Impact factor: 2.490

2.  Next-Generation Sequencing Improves Diagnosis, Prognosis and Clinical Management of Myeloid Neoplasms.

Authors:  Diego Carbonell; Julia Suárez-González; María Chicano; Cristina Andrés-Zayas; Juan Carlos Triviño; Gabriela Rodríguez-Macías; Mariana Bastos-Oreiro; Patricia Font; Mónica Ballesteros; Paula Muñiz; Pascual Balsalobre; Mi Kwon; Javier Anguita; José Luis Díez-Martín; Ismael Buño; Carolina Martínez-Laperche
Journal:  Cancers (Basel)       Date:  2019-09-13       Impact factor: 6.639
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.